Citadel Advisors’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.72M | Sell |
22,005
-89,989
| -80% | -$15.4M | ﹤0.01% | 4852 |
|
|
2025
Q4 | $18.9M | Buy |
111,994
+64,221
| +134% | +$10.4M | ﹤0.01% | 2418 |
|
|
2025
Q3 | $6.9M | Sell |
47,773
-110,612
| -70% | -$15.1M | ﹤0.01% | 3819 |
|
|
2025
Q2 | $20M | Buy |
158,385
+141,667
| +847% | +$17.4M | ﹤0.01% | 2130 |
|
|
2025
Q1 | $2.14M | Sell |
16,718
-63,759
| -79% | -$8.65M | ﹤0.01% | 5406 |
|
|
2024
Q4 | $10.6M | Buy |
+80,477
| New | +$11.3M | ﹤0.01% | 2910 |
|
|
2024
Q3 | – | Sell |
-217,695
| Closed | -$31.5M | – | 14650 |
|
|
2024
Q2 | $29.9M | Buy |
217,695
+217,690
| +4,353,800% | +$29.1M | 0.01% | 1610 |
|
|
2024
Q1 | $686 | Buy |
+5
| New | +$683 | ﹤0.01% | 14270 |
|
|
2023
Q4 | – | Sell |
-46,208
| Closed | -$5.64M | – | 14715 |
|
|
2023
Q3 | $5.65M | Buy |
46,208
+39,041
| +545% | +$4.96M | ﹤0.01% | 3464 |
|
|
2023
Q2 | $910K | Sell |
7,167
-144,473
| -95% | -$18.8M | ﹤0.01% | 6654 |
|
|
2023
Q1 | $19.6M | Sell |
151,640
-25,396
| -14% | -$3.32M | ﹤0.01% | 1937 |
|
|
2022
Q4 | $23.2M | Buy |
177,036
+39,599
| +29% | +$5.12M | 0.01% | 1811 |
|
|
2022
Q3 | $16.1M | Buy |
137,437
+98,930
| +257% | +$12.3M | ﹤0.01% | 2131 |
|
|
2022
Q2 | $4.53M | Sell |
38,507
-130,342
| -77% | -$15.5M | ﹤0.01% | 3992 |
|
|
2022
Q1 | $22M | Sell |
168,849
-112,293
| -40% | -$14.6M | ﹤0.01% | 1876 |
|
|
2021
Q4 | $42.9M | Buy |
281,142
+111,981
| +66% | +$17.3M | 0.01% | 1285 |
|
|
2021
Q3 | $27.4M | Buy |
169,161
+50,389
| +42% | +$8.48M | 0.01% | 1658 |
|
|
2021
Q2 | $19.4M | Buy |
118,772
+50,100
| +73% | +$7.72M | ﹤0.01% | 2115 |
|
|
2021
Q1 | $10.3M | Buy |
68,672
+10,377
| +18% | +$1.65M | ﹤0.01% | 2913 |
|
|
2020
Q4 | $8.83M | Sell |
58,295
-4,477
| -7% | -$640K | ﹤0.01% | 2821 |
|
|
2020
Q3 | $8.5M | Buy |
+62,772
| New | +$8.52M | ﹤0.01% | 2483 |
|
|
2020
Q2 | – | Sell |
-159,047
| Closed | -$20.3M | – | 10104 |
|
|
2020
Q1 | $17.1M | Buy |
159,047
+81,840
| +106% | +$9.42M | 0.01% | 1356 |
|
|
2019
Q4 | $9.3M | Buy |
77,207
+39,617
| +105% | +$4.42M | ﹤0.01% | 2287 |
|
|
2019
Q3 | $3.74M | Buy |
37,590
+15,130
| +67% | +$1.58M | ﹤0.01% | 3523 |
|
|
2019
Q2 | $2.45M | Buy |
22,460
+1,983
| +10% | +$211K | ﹤0.01% | 4169 |
|
|
2019
Q1 | $2.29M | Sell |
20,477
-17,425
| -46% | -$1.91M | ﹤0.01% | 4235 |
|
|
2018
Q4 | $3.65M | Sell |
37,902
-101,251
| -73% | -$10.7M | ﹤0.01% | 3247 |
|
|
2018
Q3 | $17M | Buy |
139,153
+71,072
| +104% | +$8.37M | 0.01% | 1551 |
|
|
2018
Q2 | $7.48M | Buy |
+68,081
| New | +$7.28M | ﹤0.01% | 2256 |
|
|
2018
Q1 | – | Sell |
-4,749
| Closed | -$526K | – | 8490 |
|
|
2017
Q4 | $507K | Sell |
4,749
-29,658
| -86% | -$3.17M | ﹤0.01% | 5623 |
|
|
2017
Q3 | $3.83M | Buy |
34,407
+26,550
| +338% | +$2.84M | ﹤0.01% | 2601 |
|
|
2017
Q2 | $812K | Sell |
7,857
-104,004
| -93% | -$10.2M | ﹤0.01% | 4396 |
|
|
2017
Q1 | $10.9M | Sell |
111,861
-112,263
| -50% | -$10.7M | 0.01% | 1373 |
|
|
2016
Q4 | $19.8M | Buy |
224,124
+181,758
| +429% | +$16.5M | 0.02% | 884 |
|
|
2016
Q3 | $4.09M | Sell |
42,366
-598,821
| -93% | -$57M | ﹤0.01% | 2178 |
|
|
2016
Q2 | $55M | Buy |
641,187
+589,605
| +1,143% | +$52.9M | 0.06% | 307 |
|
|
2016
Q1 | $4.48M | Buy |
51,582
+8,928
| +21% | +$798K | 0.01% | 1871 |
|
|
2015
Q4 | $4.81M | Sell |
42,654
-787,764
| -95% | -$85.5M | 0.01% | 1858 |
|
|
2015
Q3 | $84M | Buy |
830,418
+136,143
| +20% | +$16.3M | 0.08% | 248 |
|
|
2015
Q2 | $85.4M | Buy |
694,275
+608,055
| +705% | +$72.8M | 0.07% | 286 |
|
|
2015
Q1 | $9.87M | Sell |
86,220
-228,621
| -73% | -$25.2M | 0.01% | 1465 |
|
|
2014
Q4 | $31.8M | Buy |
314,841
+96,411
| +44% | +$9.37M | 0.03% | 699 |
|
|
2014
Q3 | $19.9M | Buy |
218,430
+19,677
| +10% | +$1.73M | 0.02% | 908 |
|
|
2014
Q2 | $17M | Buy |
+198,753
| New | +$15.7M | 0.02% | 909 |
|
Other funds holding IBB
CB
Citadel Advisors's IBB Position: Q1 2026 in Review
Citadel Advisors reduced its iShares Biotechnology ETF (IBB) stake by 80% in Q1 2026, selling an estimated $15.4M and leaving 22,005 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #4852.
Citadel Advisors first reported a position in IBB in Q2 2014 and has held it in 44 quarters since. The position peaked at $85.4M in Q2 2015. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Citadel Advisors held 22,005 shares of iShares Biotechnology ETF worth $3.72M as of Q1 2026.
- Citadel Advisors sold 89,989 iShares Biotechnology ETF shares in Q1 2026, an estimated $15.4M.
- iShares Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4852 holding.
- Citadel Advisors first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 44 quarters since.
- Citadel Advisors's iShares Biotechnology ETF position peaked at $85.4M in Q2 2015.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.